Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions

INTRODUCTION: This study aimed to examine the efficacy and safety of dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150) by geographic region. METHODS: Adults with chronic kidney disease (CKD) with or without type 2 diabetes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vart, Priya, Correa-Rotter, Ricardo, Hou, Fan Fan, Jongs, Niels, Chertow, Glenn M., Langkilde, Anna Maria, McMurray, John J.V., Rossing, Peter, Sjöström, C. David, Stefansson, Bergur V., Toto, Robert D., Douthat, Walter, Escudero, Elizabeth, Isidto, Rey, Khullar, Dinesh, Bajaj, Harpreet S., Wheeler, David C., Heerspink, Hiddo J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039473/
https://www.ncbi.nlm.nih.gov/pubmed/35497805
http://dx.doi.org/10.1016/j.ekir.2022.01.1060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039473/
https://www.ncbi.nlm.nih.gov/pubmed/35497805
http://dx.doi.org/10.1016/j.ekir.2022.01.1060

Ejemplares similares